Thank You! - Median Technologies

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

The latest from Median

The partnership’s aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab’s unique AI capabilities. The company is a Top 10 global oncology pharmaceutical company.

Median Technologies reports its business indicators for the first half of 2024, provide an update on recent successful business achievements.

Join us at the World Conference on Lung Cancer (WCLC) in San Diego, CA, from September 7-11, 2024. Visit us at Booth #2601 to discover the latest advancements in eyonisLCS™:

Visit our team at booth #58 to learn about our best-in-class central imaging services for oncology clinical trials.

Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.

Conferences

October 27-29, 2024

DIA Japan Annual Meeting 2024

See all conferences

Webinars

Closing the Gap: Strategies for Resolving Imaging Discrepancies in Oncology Drug Trials

See all webinars